460 related articles for article (PubMed ID: 35153195)
1. Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans.
Eng H; Dantonio AL; Kadar EP; Obach RS; Di L; Lin J; Patel NC; Boras B; Walker GS; Novak JJ; Kimoto E; Singh RSP; Kalgutkar AS
Drug Metab Dispos; 2022 May; 50(5):576-590. PubMed ID: 35153195
[TBL] [Abstract][Full Text] [Related]
2. [Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination].
Reina J; Iglesias C
Rev Esp Quimioter; 2022 Jun; 35(3):236-240. PubMed ID: 35183067
[TBL] [Abstract][Full Text] [Related]
3. Genetic Surveillance of SARS-CoV-2 M
Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
[TBL] [Abstract][Full Text] [Related]
4. A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir.
Gerhart J; Cox DS; Singh RSP; Chan PLS; Rao R; Allen R; Shi H; Masters JC; Damle B
Clin Pharmacokinet; 2024 Jan; 63(1):27-42. PubMed ID: 38177893
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the use of Paxlovid in clinical practice.
McCarthy MW
Drugs Today (Barc); 2022 Nov; 58(11):539-546. PubMed ID: 36422515
[TBL] [Abstract][Full Text] [Related]
6. Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.
Azanza JR; Mensa J; González Del Castillo J; Linares Rufo M; Molero JM; Madero Valle N; Barberán J
Rev Esp Quimioter; 2022 Aug; 35(4):357-361. PubMed ID: 35822605
[TBL] [Abstract][Full Text] [Related]
7. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
Hammond J; Leister-Tebbe H; Gardner A; Abreu P; Bao W; Wisemandle W; Baniecki M; Hendrick VM; Damle B; Simón-Campos A; Pypstra R; Rusnak JM;
N Engl J Med; 2022 Apr; 386(15):1397-1408. PubMed ID: 35172054
[TBL] [Abstract][Full Text] [Related]
8. Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants.
Pagliano P; Spera A; Sellitto C; Scarpati G; Folliero V; Piazza O; Franci G; Conti V; Ascione T
Expert Opin Drug Discov; 2023; 18(12):1301-1311. PubMed ID: 37614103
[TBL] [Abstract][Full Text] [Related]
9. Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.
Singh RSP; Toussi SS; Hackman F; Chan PL; Rao R; Allen R; Van Eyck L; Pawlak S; Kadar EP; Clark F; Shi H; Anderson AS; Binks M; Menon S; Nucci G; Bergman A
Clin Pharmacol Ther; 2022 Jul; 112(1):101-111. PubMed ID: 35388471
[TBL] [Abstract][Full Text] [Related]
10. Paxlovid: Mechanism of Action, Synthesis, and
Marzi M; Vakil MK; Bahmanyar M; Zarenezhad E
Biomed Res Int; 2022; 2022():7341493. PubMed ID: 35845944
[TBL] [Abstract][Full Text] [Related]
11. PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patients.
Hau RK; Wright SH; Cherrington NJ
Clin Transl Sci; 2022 Jul; 15(7):1599-1605. PubMed ID: 35505633
[TBL] [Abstract][Full Text] [Related]
12. Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M
Catlin NR; Bowman CJ; Campion SN; Cheung JR; Nowland WS; Sathish JG; Stethem CM; Updyke L; Cappon GD
Reprod Toxicol; 2022 Mar; 108():56-61. PubMed ID: 35101563
[TBL] [Abstract][Full Text] [Related]
13. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
[TBL] [Abstract][Full Text] [Related]
14. Nirmatrelvir Plus Ritonavir: First Approval.
Lamb YN
Drugs; 2022 Apr; 82(5):585-591. PubMed ID: 35305258
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants.
Greasley SE; Noell S; Plotnikova O; Ferre R; Liu W; Bolanos B; Fennell K; Nicki J; Craig T; Zhu Y; Stewart AE; Steppan CM
J Biol Chem; 2022 Jun; 298(6):101972. PubMed ID: 35461811
[TBL] [Abstract][Full Text] [Related]
16. Oral Nirmatrelvir-Ritonavir Use and Clinical Outcomes in Pregnant Patients With Coronavirus Disease 2019 (COVID-19).
Toure BB; Panakam A; Johns SL; Butler SK; Tuomala RE; Diouf K
Obstet Gynecol; 2024 Feb; 143(2):273-276. PubMed ID: 37963387
[TBL] [Abstract][Full Text] [Related]
17. Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Hashemian SMR; Sheida A; Taghizadieh M; Memar MY; Hamblin MR; Bannazadeh Baghi H; Sadri Nahand J; Asemi Z; Mirzaei H
Biomed Pharmacother; 2023 Jun; 162():114367. PubMed ID: 37018987
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19.
Lemaitre F; Budde K; Van Gelder T; Bergan S; Lawson R; Noceti O; Venkataramanan R; Elens L; Moes DJAR; Hesselink DA; Pawinski T; Johnson-Davis KL; De Winter BCM; Pattanaik S; Brunet M; Masuda S; Langman LJ
Ther Drug Monit; 2023 Apr; 45(2):191-199. PubMed ID: 35944126
[TBL] [Abstract][Full Text] [Related]
19. Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation.
Wong CKH; Lau KTK; Chung MSH; Au ICH; Cheung KW; Lau EHY; Daoud Y; Cowling BJ; Leung GM
Nat Med; 2024 Jan; 30(1):112-116. PubMed ID: 37913816
[TBL] [Abstract][Full Text] [Related]
20. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
Saravolatz LD; Depcinski S; Sharma M
Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
